Gynecologic Cancers

For patients with unresectable vulvar cancer, an improved ORR was observed with pembrolizumab plus cisplatin and RT followed by maintenance pembrolizumab.

Less radical surgery did not come at the expense of postoperative metrics, including 30-day readmissions, surgical findings, or receipt of adjuvant therapy.

The phase 3 ROSELLA trial results assessing relacorilant/nab-paclitaxel in patients with platinum-resistant ovarian cancer will support an upcoming NDA.

Certain subpopulations experienced significantly poorer outcomes in 2020, highlighting concerns regarding access to care.

Socioeconomic or racial disparities may contribute to unchanged overall survival among certain patients with metastatic uterine cancer.

Despite all groups completing chemoradiation within 56 days, delays contributed to a nonsignificant difference in length between Black vs White patients.

The adverse effect profile of abemaciclib plus hormonal therapy was comparable with prior reports of CDK4/6 inhibitors.

Puxitatug samrotecan was well tolerated in patients with advanced or metastatic endometrial cancer.

A slightly higher complete response rate was observed with the metformin regimen vs with the levonorgestrel-releasing IUD alone in endometrial cancer.

No deaths or significant adverse effects were reported in the screened population among those who received hysteroscopic resection for endometrial cancer.

Mirvetuximab soravtansine additionally showcased PFS, ORR, and DOR benefits over chemotherapy in FRα-positive platinum-resistant ovarian cancer.

The phase 2 trial is currently accruing additional patients with advanced mesonephric gynecologic cancer for treatment with avutometinib/defactinib.

The 2025 SGO meeting will feature readouts of potentially impactful trial data in ovarian cancer, cervical cancer, and other gynecologic malignancies.

Incorporating frailty evaluation into practice may alter clinical decision-making for preoperative planning and patient counseling for gynecologic surgery.

Barriers and gaps in treatment and care for patients diagnosed with gynecologic cancers were reported in a recent survey.

Data from KEYNOTE-868 and KEYNOTE-A18 support the approval of pembrolizumab-based therapy in endometrial and cervical cancer, respectively.

Ginger J. Gardner, MD, FACOG, walked through the strides of gynecologic cancer research and emphasized the efforts that still need to be accomplished.

A new surgical option of uterine transposition may help preserve fertility for women who have cancers of the pelvic region.

Uterine transposition is a newer tactic in the surgical oncology field to help preserve fertility for patients undergoing pelvic radiation.

As the uterus is moved to the anterior abdominal wall, patients now have a chance of preserving their fertility during radiation therapy.

Pluta Cancer Center clinicians discussed how to improve sexual health outcomes for patients diagnosed with gynecological cancer.

PAX8, a marker for aggressive disease in numerous cancer types, was more highly expressed in Black patients with uterine serous carcinoma.

Data support subcutaneous envafolimab plus lenvatinib as a promising new therapy option in advanced endometrial cancer.

The CARACO study shows that adding retroperitoneal lymphadenectomy to cytoreductive surgery did not improve survival in advanced ovarian cancer.

Learn more about a 56-year-old woman diagnosed with well-differentiated papillary mesothelioma, and how she was diagnosed and properly treated.

Approval of the self-collection solution may reduce barriers to sample collection and increase access to cervical cancer screening.

The CheckMate 358 trial assessed various doses of nivolumab with or without ipilimumab for recurrent or metastatic cervical cancer.

Developers will work with investigators of the phase 3 KEYNOTE-B21 trial to share their findings with the scientific community.

The FDA has set a Prescription Drug User Fee Act date of August 23, 2024, for dostarlimab in all types of primary advanced endometrial cancer.

Combining rintatolimod with pembrolizumab may confer a synergistic effect in patients with recurrent ovarian cancer.